Sam Brusco, Associate Editor05.15.23
Shockwave Medical has fully launched its Shockwave C2+ coronary intravascular lithotripsy (IVL) catheter to treat severely calcified coronary artery disease in select international markets.
Shockwave C2+, according to the company, offers 50% more pulses per catheter than the previous generation Shockwave C2 and is designed to treat longer calcified lesions and more difficult eccentric and nodular calcium.
“Shockwave C2+ maintains the intuitive catheter design and ease of use that are foundational to the success of Shockwave IVL and incorporates improvements that will enhance procedural efficiency and optimize the treatment of the most challenging morphologies,” Jonathan Hill, MD, Consultant Cardiologist at the Royal Brompton Hospital in London, told the press. “The extra pulses are most advantageous in areas with the highest burden of calcium, including nodular, eccentric, diffuse and multivessel calcium.”
These patients have historically had less favorable clinical outcomes that male patients with traditional therapies. The first patient was enrolled by Richard Shlofmitz, MD, chairman of the department of cardiology at St. Francis Hospital in Roslyn, N.Y.
“We are excited to initiate enrollment of the EMPOWER CAD study, the first prospective clinical study in the interventional space that is completely dedicated to female patients,” said Margaret McEntegart, MD, PhD, Director of Complex Percutaneous Coronary Intervention Program at Columbia University Medical Center/New York-Presbyterian Hospital and co-principal investigator of EMPOWER CAD, after she attended the first case performed by Dr. Shlofmitz. “This is a major step towards better understanding the optimal strategy for calcium modification in female patients, an under-represented patient population who frequently are more challenging to treat and often experience suboptimal outcomes.”
Shockwave C2+ is available for treatment of de novo coronary disease in Europe and other select geographies.
Shockwave C2+, according to the company, offers 50% more pulses per catheter than the previous generation Shockwave C2 and is designed to treat longer calcified lesions and more difficult eccentric and nodular calcium.
“Shockwave C2+ maintains the intuitive catheter design and ease of use that are foundational to the success of Shockwave IVL and incorporates improvements that will enhance procedural efficiency and optimize the treatment of the most challenging morphologies,” Jonathan Hill, MD, Consultant Cardiologist at the Royal Brompton Hospital in London, told the press. “The extra pulses are most advantageous in areas with the highest burden of calcium, including nodular, eccentric, diffuse and multivessel calcium.”
First Patient Enrolled in EMPOWER CAD Trial
The company also began enrollment for its EMPOWER CAD prospective, all-female study of percutaneous coronary intervention to confirm the benefits of coronary IVL in female patients with calcified lesions.These patients have historically had less favorable clinical outcomes that male patients with traditional therapies. The first patient was enrolled by Richard Shlofmitz, MD, chairman of the department of cardiology at St. Francis Hospital in Roslyn, N.Y.
“We are excited to initiate enrollment of the EMPOWER CAD study, the first prospective clinical study in the interventional space that is completely dedicated to female patients,” said Margaret McEntegart, MD, PhD, Director of Complex Percutaneous Coronary Intervention Program at Columbia University Medical Center/New York-Presbyterian Hospital and co-principal investigator of EMPOWER CAD, after she attended the first case performed by Dr. Shlofmitz. “This is a major step towards better understanding the optimal strategy for calcium modification in female patients, an under-represented patient population who frequently are more challenging to treat and often experience suboptimal outcomes.”
Shockwave C2+ is available for treatment of de novo coronary disease in Europe and other select geographies.